Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL6045577 | 0.98 | FAAH (0.42) | FAAHSIGMAR1PHGDHOPRL1UBE2M | |
| SCHEMBL6045579 | 0.89 | OPRL1 (0.40) | FAAHSIGMAR1PHGDHOPRL1UBE2M | |
| SCHEMBL6045421 | 0.89 | CYP2D6 (0.44) | SIGMAR1ALDH1A1 | |
| SCHEMBL6045684 | 0.87 | CHRM2 (0.47) | FAAHSIGMAR1PHGDHALDH1A1KDM4E | |
| Oxalic Acid SCHEMBL6045529 | 0.87 | CYP2D6 (0.42) | SIGMAR1ALDH1A1 | |
| SCHEMBL6045587 | 0.85 | ACHE (0.49) | SIGMAR1ALDH1A1KDM4EKCNH2 | |
| SCHEMBL6045562 | 0.85 | CHRM2 (0.43) | FAAHDCUN1D1ALDH1A1KDM4E | |
| SCHEMBL6045627 | 0.85 | ACHE (0.38) | SIGMAR1ALDH1A1KCNH2DRD4 | |
| SCHEMBL6045524 | 0.84 | CHRM2 (0.44) | SIGMAR1ALDH1A1KDM4EDRD4 | |
| SCHEMBL6045705 | 0.84 | ACHE (0.41) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | FAAH 2297/4885SIGMAR1 179/4885PHGDH 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.